W

Washington Health Institute | Clinical Research

Research site
(Unclaimed)
Location
1140 Varnum Street, NE PMB Suite 203, Washington, District of Columbia, United States of America

Site insights

Top conditions

Top treatments

Lenacapavir
Nucleos(t)Ide
Islatravir
Tenofovir Alafenamide
Budigalimab
TAF
Bictegravir
GS-6207
mRNA-1345
ABBV-382

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 15 total trials

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling
Human Immuno-deficiency Virus (HIV) Disease
Drug: Budigalimab
Drug: ABBV-382

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Enrolling
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: Placebo to DOR/ISL

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting
HIV-1 Infection
Drug: B/F/TAF
Drug: ISL

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Active, not recruiting
Pre-Exposure Prophylaxis of HIV Infection
Drug: Oral Lenacapavir (LEN)
Drug: F/TDF

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting
HIV-1-infection
Drug: Optimized Background Regimen (OBR)
Drug: Failing ARV Regimen

Trial sponsors

Gilead Sciences logo
A
George Washington University (GW) logo
AbbVie logo
Merck Sharp & Dohme (MSD) logo
Moderna logo
Pfizer logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems